Posts by: Alice Melão

News

The biologic rituximab is an acceptable and safe treatment choice for people with rheumatoid arthritis (RA)-related interstitial lung disease (ILD), and can help to maintain lung function — especially if given before the ... Read more

August 3, 2017August 3, 2017

Aradigm Asks FDA for New Drug Application for Linhaliq to Treat Bacterial Infection in NCFBE

News

Aradigm is asking the U.S. Food and Drug Administration (FDA) for permission to market its candidate therapy, Linhaliq, to treat non-cystic fibrosis bronchiectasis (NCFBE) with chronic lung infections caused by Pseudomonas aeruginosa. ... Read more

July 25, 2017July 25, 2017

ZappRx Implements Specialty Medication Prescribing Platform at 2 Pulmonary Medical Centers

Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News, Pulmonary Hypertension

Harbor-UCLA Medical Center in Torrance, California, and Phoenix-based Arizona Pulmonary Specialists — the largest U.S. private practice treating pulmonary hypertension — now offer a digital platform designed by ZappRx to facilitate the complex ... Read more

July 17, 2017July 17, 2017

Esbriet, Ofev Remain the Most Reliable Therapies for Idiopathic Pulmonary Fibrosis, Comparison Study Shows

Idiopathic Pulmonary Fibrosis, News

The first two approved therapies for idiopathic pulmonary fibrosis (IPF), Genentech’s Esbriet (pirfenidone) and Boehringer Ingelheim’s Ofev (nintedanib), are still the most reliable treatments among several approved and experimental therapies, according to a ... Read more

July 5, 2017July 5, 2017

Respiratory Hospitalization Rates May Improve Outcome Assessments in IPF Trials, Researchers Suggest

Idiopathic Pulmonary Fibrosis, News

Researchers at Columbia University propose that respiratory-related hospitalization rates are an important “patient-centered” outcome measure that should be considered in clinical trials assessing treatment effectiveness in patients with idiopathic pulmonary fibrosis (IPF), ... Read more

June 29, 2017June 29, 2017

Traditional Chinese Medicine Therapy Can Help Slow PF Progression, Study Finds

Idiopathic Pulmonary Fibrosis, News

Pulmonary rehabilitation mixture (PRM), an herbal-based formula used for decades in Chinese traditional medicine, has therapeutic potential against pulmonary fibrosis (PF) progression by targeting several molecular factors known to be involved ... Read more

June 7, 2017June 7, 2017

Researchers Uncover New Mechanism that may ‘Turn Off’ Allergic Reactions

Asthma, News

Researchers have uncovered a method to overcome inflammation and exacerbated activity of immune T-cells caused by severe allergies, according to a report published in the journal JCI Insight. The team at The ... Read more

June 2, 2017June 2, 2017

Lung Cell Regeneration Research Wins $6.9 Million NIH Grant

Idiopathic Pulmonary Fibrosis

Research focused on lung cell regeneration processes has been awarded a $6.9 million, seven-year grant by the National Institutes of Health (NIH) National Heart, Lung and Blood Institute (NHLBI), potentially ... Read more

May 19, 2017May 19, 2017

Resokine Protein Key to Regulating Inflammation and Fibrosis in Lung Disease, Study Reports

Idiopathic Pulmonary Fibrosis, News

Results from preclinical studies showed that restoring the levels of a protein called Resokine has therapeutic potential for the treatment of severe, rare pulmonary diseases characterized by inflammation and fibrosis, ... Read more

May 11, 2017May 11, 2017

Protectin DX Found to Reverse Fibrotic Process in Mice with Lung Fibrosis

Idiopathic Pulmonary Fibrosis, News

Results from a preclinical study showed that treatment with a fatty acid molecule called protectin DX (PDX) could resolve several key features of lung fibrosis in mice. The results were ... Read more